Document is current
Any future updates will be listed below
-
Authors
Iimura, Yohei
Iihara, Hirotoshi
Aoyama, Takeshi
Hayashi, Toshinobu
Ishibashi, Masaaki
Sasuga, Chieko
Furukawa, Naoki
Anzai, Eri
Ijichi, Yuki
Kuroda, Seiichiro
-
Funding
Funding for this research was provided by:
The University of Tokyo
- License Information
-
More Information
Article History
Received: 17 March 2026
Accepted: 27 May 2026
First Online: 8 June 2026
Declarations
:
: Hirotoshi Iihara served as a consultant for Astellas Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hirotoshi Iihara received lecture fees from Astellas Pharma Co., Ltd.; AstraZeneca plc; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eli Lilly and Company; Nippon Kayaku Co., Ltd.; Ohara Pharmaceutical Co., Ltd.; Sawai Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; and Yakult Honsha Co., Ltd. Yohei Iimura, Takeshi Aoyama, Toshinobu Hayashi, Masaaki Ishibashi, Chieko Sasuga, Naoki Furukawa, Eri Anzai, Yuki Ijichi, and Seiichiro Kuroda have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethical Review Board of The Institute of Medical Science, the University of Tokyo (approval number: 2023-4-0420). This study was registered in the Japan Registry of Clinical Trials (jRCT) as jRCT1030230130. Written informed consent was obtained from all the patients.
: All patients provided written informed consent.
: Not applicable.
